Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0024-3205(81)90580-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ghrelin recruits the endocannabinoid system to modulate food reward.
J Neurosci
January 2025
Carleton University, Neuroscience Department, Ottawa, ON, Canada,
Ghrelin enhances feeding by activating the growth hormone secretagogue receptor (GHSR). In the brain, GHSRs are expressed in regions responsible for regulating food motivation including the ventral tegmental area (VTA). Endogenous cannabinoids also promote food seeking behaviors through the cannabinoid receptor 1 type (CB-1Rs) in brain regions including the VTA.
View Article and Find Full Text PDFDopamine-Sensitive Anterior Cingulate Cortical Glucose-Monitoring Neurons as Potential Therapeutic Targets for Gustatory and Other Behavior Alterations.
Biomedicines
December 2024
Institute of Physiology, Medical School, University of Pécs, H-7624 Pécs, Hungary.
: The anterior cingulate cortex (ACC) is known for its involvement in various regulatory functions, including in the central control of feeding. Activation of local elements of the central glucose-monitoring (GM) neuronal network appears to be indispensable in these regulatory processes. Destruction of these type 2 glucose transporter protein (GLUT2)-equipped chemosensory cells results in multiple feeding-associated functional alterations.
View Article and Find Full Text PDFTranscranial Magnetic Stimulation Attenuates Dyskinesias and FosB and c-Fos Expression in a Parkinson's Disease Model.
Brain Sci
November 2024
Departamento de Fisiología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.
Background/objectives: Dopamine replacement therapy for Parkinson's disease (PD) may lead to disabling incontrollable movements known as L-DOPA-induced dyskinesias. Transcranial magnetic stimulation (TMS) has been applied as non-invasive therapy to ameliorate motor symptoms and dyskinesias in PD treatment. Recent studies have shown that TMS-induced motor effects might be related to dopaminergic system modulation.
View Article and Find Full Text PDFGlucagon-like peptide-1 receptor agonists (GLP1RAs) effectively reduce body weight and improve metabolic outcomes, yet established peptide-based therapies require injections and complex manufacturing. Small-molecule GLP1RAs promise oral bioavailability and scalable manufacturing, but their selective binding to human versus rodent receptors has limited mechanistic studies. The neural circuits through which these emerging therapeutics modulate feeding behavior remain undefined, particularly in comparison to established peptide-based GLP1RAs.
View Article and Find Full Text PDFAssociation of antidepressants with cataracts and glaucoma: a disproportionality analysis using the reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS) pharmacovigilance database.
CNS Spectr
January 2025
Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Article Synopsis
- Antidepressants, particularly Tricyclics (TCAs) and some new treatments, may increase the risk of cataracts, while others like Tetracyclics (TeCAs) and Monoamine Oxidase Inhibitors (MAOIs) appear to lower that risk.
- Several types of antidepressants, including SSRIs and SNRIs, have been linked to an increased risk of glaucoma, with risk ratios (RORs) showing significant associations.
- However, the study is limited by potential duplicate reports in the FDA database, and causality can't be definitively established. Overall, most antidepressants investigated were linked to lower cataract risk, but caution is needed in interpreting these findings
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!